glp-1-directed nmda receptor antagonism for obesity treatment The GLP-1 Agonists and Obesity: How Diabetes Drugs are Changing Non-Diabetic Lives — tl;dr pharmacy Harnessing GLP-1 Receptor Agonists for

The SOUL trial (NCT06659718) will investigate the effect of semaglutide on cardiovascular outcomes in patients with T2DM who have preexisting cardiovascular disease and/or CKD

Published with Habener in July 1986, their investigations revealed that the processing of preproglucagon was cell-specific and that 'the genetic determinants of the processing activity are complex and are expressed in a cell-specific manner' (Drucker, Mojsov, Habener)

Common side effects include nausea, bloating, constipation, or upset stomachespecially as your dose increases

doi: 10.2337/dc06-0042

Another study concluded that GLP-1s didnt affect psychiatric symptoms in 29 people with bipolar disorder or depression